PFM Health Sciences, LP 13D and 13G filings for Arcus Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:06 pm Sale |
2022-12-31 | 13G | Arcus Biosciences, Inc. RCUS |
PFM Health Sciences, LP | 2,703,287 3.700% |
-1,229,946 (-31.27%) |
Filing |
| 2022-10-17 4:01 pm Purchase |
2022-10-06 | 13G | Arcus Biosciences, Inc. RCUS |
PFM Health Sciences, LP | 3,933,233 5.500% |
502,223 (+14.64%) |
Filing |
| 2022-02-14 12:38 pm Purchase |
2021-12-31 | 13G | Arcus Biosciences, Inc. RCUS |
PFM Health Sciences, LP | 3,431,010 4.900% |
57,550 (+1.71%) |
Filing |
| 2021-02-16 4:10 pm Unchanged |
2020-12-31 | 13G | Arcus Biosciences, Inc. RCUS |
PFM Health Sciences, LP | 3,373,460 5.200% |
0 (Unchanged) |
Filing |
| 2020-11-09 4:01 pm Purchase |
2020-10-29 | 13G | Arcus Biosciences, Inc. RCUS |
PFM Health Sciences, LP | 3,373,460 5.200% |
3,373,460 (New Position) |
Filing |